{"entity":{"id":"cp-383","kind":"drug","name":"CP-383","aka":[],"tldr":"CP-383 is an experimental small molecule from Tasca Therapeutics, in phase 1 trials for colorectal cancer, small cell lung cancer and head and neck squamous cell carcinoma and other cancers.","summary":"CP-383 is a small molecule from Tasca Therapeutics. The registry describes CP-383 as an anti-cancer agent that inhibits pyrimidine synthesis in cancer cells; the company calls it a first-in-class inhibitor from its auto-palmitoylation platform. Its furthest stage is phase 1, for colorectal cancer, small cell lung cancer, head and neck squamous cell carcinoma and bladder cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07030257 recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Tasca Therapeutics: tascatx.com","url":"https://www.tascatx.com/pipeline"},{"label":"Tasca Therapeutics: tascatx.com","url":"https://www.tascatx.com/pipeline"},{"label":"Tasca Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07030257"},{"label":"ClinicalTrials.gov: trials of CP-383","url":"https://clinicaltrials.gov/search?intr=CP-383"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","sclc","head-and-neck","urothelial","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tasca-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07030257"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CP-383","modality":"Small molecule","mechanism":"The registry describes CP-383 as an anti-cancer agent that inhibits pyrimidine synthesis in cancer cells; the company calls it a first-in-class inhibitor from its auto-palmitoylation platform.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cp-383/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"tasca-therapeutics","kind":"company","name":"Tasca Therapeutics","route":"/companies/tasca-therapeutics/"}],"trial":[{"id":"nct07030257","kind":"trial","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07030257/"}]}}